Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2004 • 3,873 citations

The role of angiogenesis in tumor growth.

1992 • 1,267 citations

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

2004 • 855 citations

Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria

1996 • 785 citations

Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein

2000 • 778 citations

Induction of bcl-2 Expression by Phosphorylated CREB Proteins during B-Cell Activation and Rescue from Apoptosis

1996 • 410 citations

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

2005 • 358 citations

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

2005 • 335 citations

Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli

2003 • 334 citations

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

2005 • 328 citations

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism

2001 • 311 citations

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

2005 • 298 citations

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis

2003 • 272 citations

Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases

2000 • 244 citations

Insulin-like Growth Factor-I Induces bcl-2 Promoter through the Transcription Factor cAMP-Response Element-binding Protein

1999 • 200 citations

Serine/threonine phosphorylation in cytokine signal transduction

2000 • 199 citations

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein

2001 • 132 citations

Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.

2003 • 118 citations

A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase

1993 • 107 citations

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

2005 • 100 citations

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells

1998 • 100 citations

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism

2000 • 90 citations

Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma

2002 • 87 citations

Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.

2001 • 84 citations

A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells

2000 • 76 citations

Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma

2003 • 74 citations

Abrogation of c-Raf expression induces apoptosis in tumor cells

1998 • 69 citations

Raf and the road to cell survival: a tale of bad spells, ring bearers and detours

2003 • 68 citations

Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.

2001 • 62 citations

Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.

2002 • 60 citations

Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria

2001 • 58 citations

Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells

2000 • 48 citations

Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter

1996 • 40 citations

CREB Is One Component of the Binding Complex of the Ces-2/E2A-HLF Binding Element and Is an Integral Part of the Interleukin-3 Survival Signal

2001 • 36 citations

Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells

2000 • 35 citations

Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development

2004 • 27 citations

Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models

2004 • 23 citations

Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells

2000 • 22 citations

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

2004 • 19 citations

42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC)

2004 • 15 citations

A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC)

2004 • 12 citations

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

2004 • 9 citations

A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC)

2004 • 4 citations